New diagnostic tool for early detection of diseases related to involuntary childlessness – new markers of testicular and ovarian function

Infertility affects 15-20% of couples worldwide, yet its implications extend beyond reproductive health. Both men and women with infertility issues are at an increased risk of metabolic and cardiovascular diseases, primarily due to disruptions in sex hormone production. This presents a unique opportunity: since many infertility patients are in contact with healthcare systems at an early stage in life, their treatment process could serve as a crucial window for detecting and preventing serious conditions such as diabetes and cardiovascular disorders.

Objective

This project aims on developing new diagnostic tests that assess testicular and ovarian function while also identifying early markers of disease linked to infertility. The goal is to enable early intervention, improving both reproductive and overall long-term health outcomes.

A research group at Lund University has recently patented three novel biomarkers that indicate how testosterone affects the body. However, reliable diagnostic methods and clinical guidelines are required. This project aims to bridge that gap by developing standardized analysis methods for these markers, including INSL3 and three additional key indicators, ensuring that they can be used effectively in clinical settings.

Potential Impact

By integrating advanced diagnostic testing into fertility care, this initiative has the potential to redefine how infertility is managed—not just as a reproductive challenge, but as a key predictor of broader health risks. This could transform fertility clinics into preventive healthcare hubs, allowing for early disease detection and personalized treatment strategies that extend far beyond fertility alone.